Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have been given an average recommendation of “Buy” by the nine brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.8571.

A number of analysts recently commented on TEVA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $27.80 on Thursday. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $27.90. The company has a market cap of $31.89 billion, a PE ratio of 46.34, a P/E/G ratio of 1.44 and a beta of 0.67. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The business has a 50-day simple moving average of $22.08 and a two-hundred day simple moving average of $19.02.

Insider Activity

In other news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the transaction, the director directly owned 495,000 shares in the company, valued at $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the business. Steadtrust LLC lifted its stake in Teva Pharmaceutical Industries by 58.1% during the 3rd quarter. Steadtrust LLC now owns 37,300 shares of the company’s stock valued at $753,000 after acquiring an additional 13,700 shares during the period. Cantor Fitzgerald L. P. purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $1,392,000. CIBC Private Wealth Group LLC lifted its position in Teva Pharmaceutical Industries by 15.5% during the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after purchasing an additional 540 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in Teva Pharmaceutical Industries in the third quarter valued at $234,000. Finally, Centaurus Financial Inc. grew its position in Teva Pharmaceutical Industries by 25.2% during the 3rd quarter. Centaurus Financial Inc. now owns 51,612 shares of the company’s stock worth $1,043,000 after purchasing an additional 10,384 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.